MTNB Stock Forecast: Matinas BioPharma Holdings, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Matinas BioPharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (12): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MTNB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MTNB, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2024 | Maxim Group | Downgrade | Hold | — |
| 11 Oct 2023 | BTIG | Reinstates | Buy | $3.00 |
| 31 Jan 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2020 | Aegis Capital | Maintains | Buy | — |
| 27 Jan 2020 | Piper Sandler | Initiates | Overweight | — |
| 24 Jan 2020 | SunTrust Robinson Humphrey | Initiates | Buy | — |
| 26 June 2019 | H.C. Wainwright | Initiates | Buy | — |
| 26 June 2019 | HC Wainwright & Co. | Initiates | Buy | — |
| 17 May 2019 | BTIG | Initiates | Buy | — |
| 17 May 2019 | BTIG Research | Initiates | Buy | — |
| 11 Feb 2019 | Roth Capital | Initiates | Buy | — |
| 13 Nov 2018 | Maxim Group | Maintains | Buy | — |
| 13 Aug 2018 | Maxim Group | Maintains | Buy | — |
| 10 July 2018 | Maxim Group | Maintains | Buy | — |
| 1 Nov 2016 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
MTNB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MTNB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 91% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −147.5%
- Return on assets
- −60.7%
- Dividend yield
- —
Higher than 10% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Matinas BioPharma Holdings, Inc. has a market value of $902K.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$6.7M.
Free cash flow in the twelve months to 30 June 2026: −$6.4M.
Matinas BioPharma Holdings, Inc. employs 2 people.
Data provided by Twelve Data
MTNB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MTNB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Matinas BioPharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MTNB
How does Ticker Nerd's model rank MTNB?
As at 21 Nov 2026, Matinas BioPharma Holdings, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).
What is the MTNB stock forecast for 2030?
No analyst covering Matinas BioPharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTNB are extrapolating price history, which says nothing about the business.
What does Matinas BioPharma Holdings, Inc. do?
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology. The company’s platform is designed to support the delivery of a range of therapeutic modalities, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology. The company’s platform is designed to support the delivery of a range of therapeutic modalities, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its current work has centered on anti-infective applications, including MAT2203, an oral formulation of amphotericin B, alongside additional discovery programs in oncology and inflammation. Matinas BioPharma Holdings, Inc. operates from Bedminster, New Jersey and remains positioned as a developer of novel drug-delivery solutions within the healthcare and biotechnology market.
CEO Mr. Jerome D. Jabbour J.D. · 2 employees · United States · https://www.matinasbiopharma.com